By Daphne Psaledakis, Simon Lewis and Elias Biryabarema WASHINGTON (Reuters) -About 1,000 doses of Gilead Sciences Inc's drug ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...
Indian pharmaceutical giants Dr. Reddy’s Laboratories and Hetero Labs are set to disrupt HIV prevention worldwide, announcing ...
Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...
The drug lenacapavir will be distributed to Eswatini and Zambia — the first step toward providing at least 2 million doses to ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...
Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...
Lenacapavir is a twice-yearly injectable drug produced by Gilead Sciences that is aimed at preventing HIV infection. In 2024, ...
Discover how lenacapavir and bNAbs show high HIV-1 suppression, low resistance, and promising outcomes for future treatment ...
South Africa takes the lead in HIV prevention with a groundbreaking twice-a-year injection being added to the Essential Medicines List.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback